US › Healthcare

Unicycive Therapeutics Inc (UNCY)

US · Healthcare · Biotechnology

$4.77-0.21%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.7M

EPS

$-0.06

EPS estimate

$-0.34

EPS came in at -0.06 against a street estimate of -0.34 — a beat of 82.4%.

Key statistics

Market cap

$144.9M

Forward P/E

1.7

P/B

2.77

Book value

$1.91

EPS (TTM)

$-1.75

52-week high

$8.74

52-week low

$3.71

50-day MA

$5.29

200-day MA

$6.41

Beta

1.78

Analyst view

Analysts rate Unicycive Therapeutics Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $29.60.

Shareholding

Insiders

2.26%

Institutions

42.25%

Largest institutional holders

Fund	Stake
Octagon Capital Advisors LP	3.59%
Nantahala Capital Management, LLC	3.37%
Vanguard Capital Management, LLC	2.91%
Vivo Capital, LLC	1.97%
Logos Global Management LP	1.70%
Diadema Partners LP	1.09%
Millennium Management LLC	0.97%
Geode Capital Management, LLC	0.73%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Unicycive Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.